LGR5 and ovarian carcinoma: This study focused on RSPO1 receptor-binding domain (Fu1-Fu2) that deliver cytotoxic agents or immune-modulating therapies directly to LGR5-expressing ovarian cancer cells and was very effective in a LGR5-rich ovarian cancer xenograft model [140].